Table 1 Basic clinical characteristics in the BUDO and BUDAO groups.

From: Prolonged infusion of bivalirudin after elective percutaneous coronary intervention protects against procedural myocardial injury (a COBER study)—a randomized trial

Variables

BUDO group (n = 165)

BUDAO group (n = 165)

P value

Age (years)

65.63 ± 11.22

66.35 ± 10.80

0.552

Male gender (%)

115 (69.70%)

119 (72.12%)

0.716

Height (cm)

165.98 ± 7.93

166.07 ± 7.23

0.913

Body weight (kg)

68.76 ± 11.98

67.92 ± 11.30

0.512

Hyperlipidemia (%)

118 (71.52%)

114 (69.09%)

0.718

Hypertension (%)

129 (78.18%)

118 (71.52%)

0.204

Diabetes mellitus (%)

50 (30.30%)

62 (37.58%)

0.201

Current smoker (%)

71 (43.03%)

75(45.45%)

0.740

Renal insufficiency (%)

15 (9.09%)

12 (7.27%)

0.689

Biochemical indexes

 WBC (^109)

6.52 ± 1.55

6.46 ± 1.46

0.709

 RBC (^1012)

4.34 ± 0.56

4.25 ± 0.60

0.182

 Hb (g/L)

132.43 ± 16.98

129.93 ± 16.41

0.175

 BG (mmol/L)

6.31 ± 1.90

6.39 ± 2.02

0.700

 BUA (μmol/L)

359.41 ± 132.18

348.99 ± 123.63

0.460

 TG (mmol/L)

1.70 ± 0.94

1.68 ± 0.99

0.854

 TC (mmol/L)

4.07 ± 1.14

4.04 ± 1.21

0.834

 HDL-C (mmol/L)

1.00 ± 0.25

0.96 ± 0.23

0.184

 LDL-C (mmol/L)

2.31 ± 0.93

2.33 ± 1.00

0.871

 PLT (^109)

193.83 ± 61.74

200.47 ± 57.05

0.311

 APTT (sec)

27.92 ± 3.35

28.30 ± 3.38

0.299

 TT (sec)

18.45 ± 9.07

18.30 ± 4.50

0.845

 FIB (g/L)

3.32 ± 1.07

3.43 ± 1.08

0.319

Previous drug therapy

 Anti-platelet medication (%)

81 (49.09%)

73 (44.24%)

0.440

 ACEI/ARB (%)

94 (56.97%)

108 (65.45%)

0.142

 β-blocker (%)

86 (52.12%)

98 (59.39%)

0.223

 CCB (%)

58 (35.15%)

52 (31.52%)

0.817

 Statin (%)

89 (53.94%)

80 (48.48%)

0.378

Echocardiographic parameters

 AOD (mm)

32.97 ± 3.27

32.55 ± 3.37

0.247

 IVSD (mm)

10.32 ± 1.77

10.56 ± 2.34

0.288

 LVDD (mm)

49.21 ± 5.40

49.27 ± 5.83

0.922

 LVPWD (mm)

9.49 ± 1.35

9.48 ± 1.18

0.931

 LVDS (mm)

32.73 ± 6.14

33.04 ± 6.68

0.668

 LVEF (%)

59.51 ± 9.12

58.92 ± 9.55

0.568

  1. Data were expressed as n (%), mean ± SD. BUDO Bivalirudin use during operation; BUDAO Bivalirudin use during and after operation; WBC White blood cell; RBC Red blood cell; Hb Hemoglobin; BG Blood glucose; BUA Blood urine acid; TG Triglyceride; TC Total cholesterol; HDL-C High-density lipoprotein cholesterol; LDL-C Low-density lipoprotein cholesterol; PLT Platelet; APTT Activated partial thromboplastin time; TT Thrombin time; FIB Fibrinogen; ACEI/ARB Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; CCB calcium channel blockers; AOD Aortic diameter; IVSD Interventricular septum diameter; LVDD Left ventricular enddiastolic diameter; LVPWD Left ventricular posterior wall diameter; LVDS Left ventricular endsystolic diameter; LVEF Left ventricular ejection fraction.
Back to article page